STOKE THERAPEUTICS, INC.
45 Wiggins Avenue
Bedford, MA 01730
June 17, 2024
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention: Office of Life Sciences
| Re: | Stoke Therapeutics, Inc. |
Registration Statement on Form S-3
Filed June 13, 2024
File No. 333-280172
Via EDGAR - Acceleration Request
Requested Date: June 20, 2024
Requested Time: 4:00 p.m. Eastern Time
Ladies and Gentlemen:
Stoke Therapeutics, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to make the above-captioned Registration Statement on Form S-3 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable.
The Registrant hereby authorizes Robert A. Freedman or Julia Forbess, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.
The Registrant requests that it be notified of such effectiveness by a telephone call to Ms. Forbess at (415) 875-2420 or, in her absence, to Mr. Freedman at (206) 389-4524.
* * *
| Sincerely, | ||
| STOKE THERAPEUTICS, INC. | ||
| By: | /s/ Thomas Leggett | |
| Thomas Leggett Chief Financial Officer | ||
| cc: | Edward M. Kaye, Chief Executive Officer |
Jonathan Allan, General Counsel
Stoke Therapeutics, Inc.
Robert A. Freedman, Esq.
Julia Forbess, Esq.
Fenwick & West LLP